Motley Fool Premium
  1. Stocks
    2. /
  2. NervGen Pharma (TSXV: NGEN)
    3. /

TSXV:NGEN (NervGen Pharma)

About NGEN

NervGen Pharma Corp. (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTP¿ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • NervGen Pharma (TSXV: NGEN) Latest News

    a sign flashes global stock data
    Tech Stocks

    3 TSX Stocks That Could Turn $15,000 Into $150,000

    | Amy Legate-Wolfe

    These TSX stocks offer three different opportunities, but each could be a multi bagger in the works.

    Read more »

    senior man and woman stretch their legs on yoga mats outside
    Stocks for Beginners

    This Tiny Canadian Stock Could Skyrocket if That Drug Trial Succeeds

    | Amy Legate-Wolfe

    This pharmacy stock may be small, but it could become quite mighty.

    Read more »